Abstract
Purpose
The aim of this retrospective study is to evaluate the feasibility and efficacy of concurrent chemoradiotherapy (CCRT) or sequential chemoradiotherapy (SCRT) with capecitabine and cisplatin for elderly patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Methods
A total of 75 patients elder than 65 years with histologically proven stage II–III ESCC were enrolled, in whom 40 patients were treated with CCRT consisted of two cycles of intravenous cisplatin and oral capecitabine during and after radiotherapy and 35 patients were treated with SCRT as two cycles of capecitabine plus cisplatin before and after radiotherapy. Response rate, overall survival, progression-free survival and toxicity were compared.
Results
The overall response rate (CR + PR) in the CCRT group (91.6 %) was significantly higher than that in the SCRT group (67.7 %), P = 0.023. The median PFS and median OS were significantly higher in CCRT group (19.7 and 33.6 months) than those in SCRT group (11.6 and 15.7 months), P < 0.05. The acute toxic effect was more severe in the CCRT group than in the SCRT group, but the grade 3–4 acute toxicities were similar in two groups.
Conclusions
It suggested that both CCRT and SCRT with capecitabine and cisplatin are tolerable and effective for elderly patients with locally advanced ESCC. Concurrent CRT might be superior to SCRT.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
al-Sarraf M, Martz K, Herskovic A et al (1997) Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 15:277–284
Anderson SE, Minsky BD, Bains M, Hummer A, Kelsen D, Ilson DH (2007) Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer 96:1823–1827. doi:10.1038/sj.bjc.6603821
Bedenne L, Michel P, Bouche O et al (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25:1160–1168. doi:10.1200/JCO.2005.04.7118
Bonavina L, Incarbone R, Saino G, Clesi P, Peracchia A (2003) Clinical outcome and survival after esophagectomy for carcinoma in elderly patients. Dis Esophagus 16:90–93. doi:10.1046/j.1442-2050.2003.00300.x
Cooper JS, Guo MD, Herskovic A et al (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281:1623–1627. doi:10.1001/jama.281.17.1623
CTEP: Common Terminology Criteria for Adverse Events, Version 3.0. (2006) DCTD, NCI, NIH, DHHS. (http://ctep.cancer.gov)
Daly JM, Fry WA, Little AG et al (2000) Esophageal cancer: results of an American College of Surgeons patient care evaluation study. J Am Coll Surg 190:562–572. doi:10.1016/S1072-7515(00)00238-6
Kim JG, Sohn SK, Kim DH et al (2005) Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 93:1117–1121. doi:10.1038/sj.bjc.6602849
Koo DH, Park SI, Kim YH et al (2011) Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data. Cancer Chemother Pharmacol 69:655–663. doi:10.1007/s00280-011-1750-5
Lee SS, Kim SB, Park SI et al (2007) Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. Jpn J Clin Oncol 37:829–835. doi:10.1093/jjco/hym117
Lee J, Im YH, Cho EY et al (2008) A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 62:77–84. doi:10.1007/s00280-007-0577-6
Lee SJ, Ahn BM, Kim JG et al (2009) Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study. J Korean Med Sci 24:120–125. doi:10.3346/jkms.2009.24.1.120
Li BS, Zhou T, Wang ZT et al (2009) Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and Capecitabine, Cisplatin for locally advanced esophageal squamous cell carcinoma. Radiother Oncol 93:458–461. doi:10.1016/j.radonc.2009.08.002
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108. doi:10.3322/canjclin.55.2.74
Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R (2003) Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 21:3098–3104. doi:10.1200/JCO.2003.02.505
Schuller J, Cassidy J, Dumont E et al (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291–297. doi:10.1007/s002800050043
Smith GL, Smith BD, Buchholz TA et al (2009) Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: the SEER-Medicare Cohort. Int J Radiat Oncol Biol Phys 74:482–489. doi:10.1016/j.ijrobp.2008.08.046
Stahl M, Stuschke M, Lehmann N et al (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310–2317. doi:10.1200/JCO.2005.00.034
Suntharalingam M, Moughan J, Coia LR et al (2005) Outcome results of the 1996–1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus. J Clin Oncol 23:2325–2331. doi:10.1200/JCO.2005.00.448
Takeuchi S, Ohtsu A, Doi T et al (2007) A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer. Am J Clin Oncol 30:607–611. doi:10.1097/COC.0b013e3180ca7c84
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216. doi:10.1093/jnci/92.3.205
Tougeron D, Di Fiore F, Thureau S et al (2008) Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer 99:1586–1592. doi:10.1038/sj.bjc.6604749
van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084. doi:10.1056/NEJMoa1112088
Wakui R, Yamashita H, Okuma K et al (2010) Esophageal cancer: definitive chemoradiotherapy for elderly patients. Dis Esophagus 23:572–579. doi:10.1111/j.1442-2050.2010.01062.x
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Ligang Xing and Yemin Liang have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Xing, L., Liang, Y., Zhang, J. et al. Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer. J Cancer Res Clin Oncol 140, 867–872 (2014). https://doi.org/10.1007/s00432-014-1615-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-014-1615-5